# A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

> **NCT00743860** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 20 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** darapladib

## Key facts

- **NCT ID:** NCT00743860
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743860, "A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00743860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*